Biogen Inc.

0R1B · LSE

252.23USD+0.23 (+0.09%)

Price History

Full chart

Market Stats

Previous Close252.00

Open250.01

Day Range249.50 – 253.00

52-Week Range138.07 – 230.23

Volume312

Market Cap32.54B

P/E (TTM)0.00

Forward P/E0.00

Dividend Yield0.00%

Beta0.17

50-Day Avg0.00

200-Day Avg0.00

About

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Company Details

CEOMr. Christopher A. Viehbacher
Employees7.50K
Headquarters225 Binney Street, Cambridge, MA, United States, 02142, UK
Websitehttps://www.biogen.com

Leadership

Mr. Christopher A. ViehbacherPresident, CEO & Director · b. 1961
Ms. Robin C. KramerExecutive VP & CFO · b. 1966
Ms. Nicole MurphyExecutive VP and Head of Pharmaceutical Operations & Technology · b. 1973
Dr. Priya Singhal M.D., M.P.H.Executive VP & Head of Development · b. 1968
Mr. Sean GodboutVP, Chief Accounting Officer & Global Corporate Controller · b. 1974
Mr. Guy HadariChief Information Officer
Mr. Tim Power M.B.A., Ph.D.Head of Investor Relations
Mr. Michael John Parini J.D.Chief Legal Officer · b. 1974
Ms. Natacha GassenbachChief Communication Officer & Head of Corporate Affairs
Mr. Adam Keeney Ph.D.Executive VP & Head of Corporate Development · b. 1977

Financials

Income Statement

Currency: USD	1986-12-31	1987-12-31	1988-12-31	1989-12-31	1990-12-31	1991-12-31	1992-12-31	1993-12-31	1994-12-31	1995-12-31	1996-12-31	1997-12-31	1998-12-31	1999-12-31	2000-12-31	2001-12-31	2002-12-31	2003-12-31	2004-12-31	2005-12-31	2006-12-31	2007-12-31	2008-12-31	2009-12-31	2010-12-31	2011-12-31	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31

Currency: USD	1986-12-31	1987-12-31	1988-12-31	1989-12-31	1990-12-31	1991-12-31	1992-12-31	1993-12-31	1994-12-31	1995-12-31	1996-12-31	1997-12-31	1998-12-31	1999-12-31	2000-12-31	2001-12-31	2002-12-31	2003-12-31	2004-12-31	2005-12-31	2006-12-31	2007-12-31	2008-12-31	2009-12-31	2010-12-31	2011-12-31	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	6.40M	8.60M	20.60M	28.50M	50.10M	61.40M	123.70M	136.40M	156.34M	151.69M	277.09M	434.04M	557.59M	794.43M	925.66M	1.04B	404.22M	186.13M	1.60B	1.71B	2.68B	3.17B	4.10B	4.38B	4.72B	5.05B	5.51B	6.93B	9.70B	9.32B	10.19B	10.99B	12.05B	12.71B	12.36B	10.40B	9.43B	9.42B	9.27B	9.53B
Growth (%)	-	+34.38%	+139.53%	+38.35%	+75.79%	+22.55%	+101.47%	+10.27%	+14.62%	-2.98%	+82.67%	+56.64%	+28.46%	+42.48%	+16.52%	+12.60%	-61.22%	-53.95%	+757.35%	+7.38%	+56.57%	+18.21%	+29.19%	+6.83%	+7.75%	+7.04%	+9.23%	+25.70%	+39.97%	-3.94%	+9.37%	+7.81%	+9.67%	+5.49%	-2.82%	-15.81%	-9.32%	-0.17%	-1.60%	+2.88%
Cost of Revenue	23.30M	21.00M	21.10M	25.20M	35.40M	43.30M	2.20M	5.50M	9.95M	10.50M	28.52M	50.19M	74.51M	111.00M	125.20M	136.51M	1.46M	284.74M	554.32M	373.61M	274.38M	335.19M	401.99M	382.10M	400.26M	466.78M	545.49M	857.70M	1.17B	1.62B	1.81B	2.09B	2.20B	2.42B	2.26B	2.60B	2.80B	3.03B	2.98B	3.08B
Gross Profit	-16.90M	-12.40M	-500.00K	3.30M	14.70M	18.10M	121.50M	130.90M	146.40M	141.19M	248.56M	383.86M	483.08M	683.43M	800.47M	905.80M	402.76M	-98.61M	1.04B	1.34B	2.41B	2.84B	3.70B	4.00B	4.32B	4.58B	4.97B	6.07B	8.53B	7.70B	8.39B	8.90B	9.86B	10.29B	10.09B	7.81B	6.64B	6.39B	6.28B	6.45B
Gross Margin	-264.06%	-144.19%	-2.43%	11.58%	29.34%	29.48%	98.22%	95.97%	93.64%	93.08%	89.71%	88.44%	86.64%	86.03%	86.47%	86.90%	99.64%	-52.98%	65.26%	78.20%	89.77%	89.43%	90.19%	91.27%	91.51%	90.75%	90.11%	87.63%	87.93%	82.59%	82.28%	81.03%	81.77%	80.97%	81.69%	75.03%	70.35%	67.84%	67.80%	67.70%
Operating Expense	12.20M	11.80M	11.40M	12.30M	13.90M	19.40M	92.90M	109.20M	148.30M	133.74M	207.74M	234.89M	292.44M	367.18M	472.11M	545.60M	188.89M	771.06M	998.08M	1.10B	1.97B	2.06B	2.48B	2.70B	3.07B	2.86B	3.13B	3.58B	4.56B	4.13B	3.92B	4.17B	4.69B	4.46B	6.29B	4.94B	4.36B	4.76B	4.16B	3.91B
Operating Income	-29.10M	-24.20M	-11.90M	-9.00M	800.00K	-1.30M	28.60M	21.70M	-1.91M	7.45M	40.83M	148.97M	190.64M	316.25M	328.36M	360.20M	213.88M	-869.67M	43.42M	236.04M	440.02M	779.77M	1.21B	1.30B	1.25B	1.72B	1.84B	2.49B	3.97B	3.57B	4.47B	4.74B	5.16B	5.83B	3.80B	2.87B	2.27B	1.63B	2.12B	2.54B
Operating Margin	-454.69%	-281.40%	-57.77%	-31.58%	1.60%	-2.12%	23.12%	15.91%	-1.22%	4.91%	14.73%	34.32%	34.19%	39.81%	35.47%	34.56%	52.91%	-467.23%	2.72%	13.77%	16.40%	24.59%	29.62%	29.59%	26.48%	34.16%	33.34%	35.92%	40.89%	38.32%	43.81%	43.09%	42.83%	45.85%	30.76%	27.54%	24.11%	17.32%	22.92%	26.69%
EBITDA	-25.00M	-20.40M	-8.80M	-5.70M	4.60M	3.80M	35.70M	28.40M	6.15M	18.36M	56.09M	168.26M	215.23M	347.35M	530.45M	430.47M	257.75M	-804.13M	522.43M	668.05M	868.93M	1.33B	1.67B	1.80B	1.62B	2.10B	2.26B	3.04B	4.61B	4.17B	5.15B	5.46B	5.81B	6.29B	5.73B	2.49B	4.36B	2.04B	2.83B	3.32B
EBITDA Margin	-390.63%	-237.21%	-42.72%	-20.00%	9.18%	6.19%	28.86%	20.82%	3.93%	12.10%	20.24%	38.77%	38.60%	43.72%	57.30%	41.30%	63.76%	-432.02%	32.74%	38.98%	32.39%	41.98%	40.76%	41.04%	34.39%	41.66%	40.93%	43.91%	47.54%	44.76%	50.51%	49.66%	48.23%	49.50%	46.38%	23.90%	46.19%	21.65%	30.53%	34.87%
Net Income	-28.20M	-22.60M	-1.20M	3.20M	7.70M	7.20M	38.30M	32.40M	-4.90M	5.66M	40.53M	89.17M	138.70M	220.45M	333.58M	272.68M	148.09M	-875.10M	25.09M	160.71M	217.51M	638.17M	783.17M	970.13M	1.01B	1.23B	1.38B	1.86B	2.93B	3.55B	3.70B	2.54B	4.43B	5.89B	4.00B	1.56B	3.05B	1.16B	1.63B	1.29B
Net Income Margin	-440.63%	-262.79%	-5.83%	11.23%	15.37%	11.73%	30.96%	23.75%	-3.13%	3.73%	14.63%	20.54%	24.87%	27.75%	36.04%	26.16%	36.64%	-470.14%	1.57%	9.38%	8.11%	20.12%	19.11%	22.16%	21.31%	24.45%	25.02%	26.86%	30.25%	38.05%	36.32%	23.10%	36.76%	46.32%	32.38%	14.96%	32.30%	12.33%	17.61%	13.56%
R&D	-	-	-	-	-	-	-	-	91.21M	87.45M	132.38M	145.50M	177.23M	221.15M	302.84M	314.56M	100.87M	1.06B	685.87M	747.67M	718.39M	925.16M	1.07B	1.28B	1.25B	1.22B	1.38B	1.46B	1.89B	2.01B	1.97B	2.25B	2.60B	2.09B	3.79B	2.27B	1.96B	2.21B	1.76B	1.78B
R&D as % of Total Revenue	-	-	-	-	-	-	-	-	58.34%	57.65%	47.78%	33.52%	31.78%	27.84%	32.72%	30.18%	24.95%	567.51%	42.98%	43.63%	26.78%	29.17%	26.16%	29.31%	26.47%	24.16%	25.00%	21.00%	19.51%	21.59%	19.36%	20.51%	21.55%	16.44%	30.67%	21.78%	20.76%	23.44%	18.94%	18.66%
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.31M	3.95M	3.55M	15.18M	18.90M	9.65M	871.00K	40.50M	52.00M	35.80M	36.10M	33.00M	36.50M	31.90M	29.50M	95.50M	260.00M	250.80M	200.60M	256.20M	291.00M	289.90M	263.70M	268.60M	250.30M	267.50M
Interest Expense % of Total Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.47%	0.38%	0.88%	8.16%	1.18%	0.56%	0.03%	1.28%	1.27%	0.82%	0.77%	0.65%	0.66%	0.46%	0.30%	1.02%	2.55%	2.28%	1.66%	2.02%	2.36%	2.79%	2.80%	2.85%	2.70%	2.81%

Balance Sheet

Currency: USD	1986-12-31	1987-12-31	1988-12-31	1989-12-31	1990-12-31	1991-12-31	1992-12-31	1993-12-31	1994-12-31	1995-12-31	1996-12-31	1997-12-31	1998-12-31	1999-12-31	2000-12-31	2001-12-31	2002-12-31	2003-12-31	2004-12-31	2005-12-31	2006-12-31	2007-12-31	2008-12-31	2009-12-31	2010-12-31	2011-12-31	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31

Currency: USD	1986-12-31	1987-12-31	1988-12-31	1989-12-31	1990-12-31	1991-12-31	1992-12-31	1993-12-31	1994-12-31	1995-12-31	1996-12-31	1997-12-31	1998-12-31	1999-12-31	2000-12-31	2001-12-31	2002-12-31	2003-12-31	2004-12-31	2005-12-31	2006-12-31	2007-12-31	2008-12-31	2009-12-31	2010-12-31	2011-12-31	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	100.90M	80.70M	80.90M	145.20M	158.50M	253.10M	311.20M	357.00M	377.86M	469.20M	634.57M	813.83M	924.72M	1.28B	1.43B	1.72B	2.01B	9.50B	9.17B	8.37B	8.55B	8.63B	8.48B	8.55B	8.09B	9.05B	10.13B	11.86B	14.31B	19.50B	22.88B	23.65B	25.29B	27.23B	24.62B	23.88B	24.55B	26.84B	28.05B	29.44B
Total Liabilities	11.60M	12.80M	12.90M	6.00M	12.80M	14.10M	26.20M	31.80M	47.93M	86.22M	150.20M	277.53M	206.10M	298.44M	325.45M	372.21M	411.57M	2.45B	2.34B	1.46B	1.40B	3.09B	2.67B	2.29B	2.64B	2.62B	3.17B	3.24B	3.50B	10.13B	10.75B	11.05B	12.26B	13.90B	13.93B	12.92B	11.17B	12.05B	11.33B	11.18B
Total Equity	89.30M	67.90M	68.00M	139.20M	145.70M	239.00M	285.00M	325.20M	329.93M	382.98M	484.37M	536.29M	718.61M	979.53M	1.11B	1.35B	1.60B	7.05B	6.83B	6.91B	7.15B	5.53B	5.81B	6.22B	5.40B	6.43B	6.96B	8.62B	10.81B	9.37B	12.14B	12.61B	13.04B	13.34B	10.70B	10.90B	13.40B	14.80B	16.72B	18.26B
Cash	70.50M	54.40M	54.30M	33.20M	12.60M	56.60M	85.90M	74.50M	54.68M	45.77M	62.03M	70.36M	25.45M	56.92M	48.74M	54.04M	45.11M	314.85M	209.45M	568.17M	661.38M	659.66M	622.38M	581.89M	759.60M	514.54M	570.72M	602.56M	1.20B	1.31B	2.33B	1.57B	1.22B	2.91B	1.33B	2.26B	3.42B	1.05B	2.38B	3.01B
Total Debt	4.40M	5.20M	4.80M	-	-	-	-	-	-	34.49M	66.27M	91.55M	80.33M	113.06M	109.32M	82.16M	42.30M	887.27M	850.31M	43.44M	96.69M	1.56B	1.11B	1.10B	1.20B	1.06B	1.14B	595.93M	585.20M	6.53B	6.52B	5.94B	5.94B	6.44B	7.91B	7.69B	6.71B	7.43B	6.72B	6.95B
Net Debt	-66.10M	-49.20M	-49.50M	-33.20M	-12.60M	-56.60M	-85.90M	-74.50M	-54.68M	-11.28M	4.24M	21.19M	54.88M	56.14M	60.58M	28.12M	-2.81M	572.42M	640.86M	-524.72M	-564.68M	903.32M	490.71M	518.08M	443.93M	549.56M	-570.72M	-602.56M	-1.20B	5.22B	4.19B	4.36B	4.71B	3.53B	6.58B	5.43B	3.29B	6.38B	4.34B	3.94B

Cash Flow

Currency: USD	1989-12-31	1990-12-31	1991-12-31	1992-12-31	1993-12-31	1994-12-31	1995-12-31	1996-12-31	1997-12-31	1998-12-31	1999-12-31	2000-12-31	2001-12-31	2002-12-31	2003-12-31	2004-12-31	2005-12-31	2006-12-31	2007-12-31	2008-12-31	2009-12-31	2010-12-31	2011-12-31	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31

Currency: USD	1989-12-31	1990-12-31	1991-12-31	1992-12-31	1993-12-31	1994-12-31	1995-12-31	1996-12-31	1997-12-31	1998-12-31	1999-12-31	2000-12-31	2001-12-31	2002-12-31	2003-12-31	2004-12-31	2005-12-31	2006-12-31	2007-12-31	2008-12-31	2009-12-31	2010-12-31	2011-12-31	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-7.50M	10.70M	5.90M	43.10M	47.60M	34.89M	9.45M	46.54M	97.63M	167.84M	272.29M	365.94M	316.36M	267.08M	219.21M	727.99M	889.50M	841.27M	1.02B	1.56B	1.07B	1.62B	1.73B	1.88B	2.35B	2.94B	3.72B	4.52B	4.55B	6.19B	7.08B	4.23B	3.64B	1.38B	1.55B	2.88B	2.20B
Investing Cash Flow	-50.90M	-29.50M	-48.30M	-23.90M	-66.70M	-70.30M	-92.31M	-82.05M	-155.20M	-158.68M	-210.08M	-105.00M	-252.91M	-289.51M	-278.93M	-382.43M	417.74M	-599.77M	-286.57M	-365.87M	-395.03M	345.32M	-1.65B	-950.34M	-1.60B	-1.54B	-4.55B	-2.48B	-2.96B	-2.05B	470.50M	-608.60M	-563.70M	1.59B	-4.09B	-799.20M	-1.37B
Financing Cash Flow	64.50M	-1.80M	86.50M	10.00M	7.80M	15.54M	73.95M	51.77M	65.90M	-54.08M	-30.73M	-269.14M	-58.16M	14.26M	51.19M	-450.96M	-948.52M	-148.41M	-735.22M	-1.24B	-724.15M	-1.78B	-319.86M	-877.48M	-716.50M	-755.90M	986.40M	-987.80M	-2.38B	-4.47B	-5.86B	-5.27B	-2.09B	-1.76B	137.00M	-683.50M	-301.90M
Capital Expenditure	3.10M	11.10M	8.40M	9.40M	10.80M	43.67M	50.31M	65.64M	35.55M	33.61M	86.33M	199.12M	195.53M	165.90M	301.25M	369.76M	318.38M	198.31M	284.11M	275.95M	165.65M	173.06M	252.18M	254.55M	246.30M	287.80M	643.00M	727.70M	1.96B	886.10M	669.50M	551.80M	294.90M	243.20M	311.40M	153.70M	153.80M
Free Cash Flow	-10.60M	-400.00K	-2.50M	33.70M	36.80M	-8.78M	-40.86M	-19.10M	62.08M	134.23M	185.96M	166.82M	120.82M	13.32M	-82.03M	358.22M	571.13M	642.96M	736.53M	1.29B	909.25M	1.45B	1.48B	1.63B	2.10B	2.65B	3.07B	3.79B	2.59B	5.30B	6.41B	3.68B	3.35B	1.14B	1.24B	2.72B	2.05B
Dividends Paid	2.70M	5.90M	2.90M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-
FCF to OCF	141.33%	-3.74%	-42.37%	78.19%	77.31%	-25.18%	-432.43%	-41.03%	63.59%	79.97%	68.30%	45.59%	38.19%	4.99%	-37.42%	49.21%	64.21%	76.43%	72.16%	82.36%	84.59%	89.35%	85.40%	86.46%	89.50%	90.22%	82.70%	83.91%	56.87%	85.68%	90.54%	86.95%	91.90%	82.43%	79.87%	94.65%	93.02%
Dividend Paid to FCF	-25.47%	-1475.00%	-116.00%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00%	-	-	-	-

Earnings

Report Date	Mar 31, 2018	Jun 30, 2018	Sep 30, 2018	Dec 31, 2018	Mar 31, 2019	Jul 23, 2019	Oct 22, 2019	Jan 30, 2020	Apr 22, 2020	Jul 22, 2020	Oct 21, 2020	Feb 3, 2021	Apr 22, 2021	Jul 22, 2021	Oct 20, 2021	Feb 3, 2022	May 3, 2022	Jul 20, 2022	Oct 25, 2022	Feb 15, 2023	Apr 25, 2023	Jul 25, 2023	Nov 8, 2023	Feb 13, 2024	Apr 24, 2024	Aug 1, 2024	Oct 30, 2024	Feb 12, 2025	May 1, 2025	Jul 31, 2025	Oct 30, 2025	Feb 6, 2026	Apr 29, 2026	Jul 29, 2026	Oct 28, 2026
EPS Estimate	-	-	-	-	-	9.15	9.17	8.34	9.14	10.26	8.84	4.58	5.34	5.68	4.77	3.39	3.62	5.25	4.77	4.05	3.40	4.02	4.36	2.95	3.67	4.07	3.77	3.41	3.56	3.88	3.88	1.63	3.01	2.07	2.03
EPS Actual	5.54	4.18	7.15	4.73	7.15	7.85	8.39	8.08	8.08	9.58	4.46	2.32	2.69	2.99	2.22	2.50	2.06	7.24	7.84	3.79	2.67	4.07	-0.47	1.71	2.70	4.00	2.66	1.83	1.64	4.33	4.81	-0.33	2.15	0.66	-
Surprise	-	-	-	-	-	-14.24%	-8.48%	-3.13%	-11.57%	-6.59%	-49.52%	-49.26%	-49.56%	-47.39%	-53.56%	-26.36%	-43.14%	37.84%	64.28%	-6.40%	-21.43%	1.14%	-110.79%	-41.91%	-26.53%	-1.72%	-29.47%	-46.45%	-53.92%	11.53%	23.97%	-120.45%	-28.47%	-68.32%	-
Timing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	After-hours	After-hours	After-hours	After-hours	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market

Key Statistics & Ratios

Market Cap32.54B

Enterprise Value40.78B

Trailing P/E0.00

Forward P/E0.00

Price / Sales0.00

Price / Book0.00

Book Value127.61

Revenue (TTM)10.03B

Gross Profit (TTM)7.85B

EBITDA3.36B

Profit Margin8.32%

Operating Margin25.06%

Return on Equity4.58%

Return on Assets5.21%

Shares Outstanding0

Shares Float147.22M

Beta0.17

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%